Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
June 2011, Vol 2, No 3
June 2011, Vol 2, No 3
ASCO Calls for Open Discussions and Individualized Care for Patients with Advanced Cancer
Health Policy
,
Policies & Guidelines
June 2011, Vol 2, No 3
Frank discussions with patients about their advanced cancer are challenging for physicians and their patients; however, avoiding such interactions is not a viable option, according to the American Society of Clinical Oncology (ASCO).
Read Article
Cancer Drug Use and Costs Sharply Rising
Health Policy
,
Policies & Guidelines
June 2011, Vol 2, No 3
There is no end in sight to the rising cost of fighting cancer, according to Medco’s 2011
Drug Trend Report
(www.drugtrendreport.com/2011-report), which forecasted the cost of cancer drugs will grow 34% to 42% over the next 3 years.
Read Article
Humana’s Real-World Data Confirm Cost-Savings with the 21-Gene Recurrence Score Assay
Health Policy
,
Policies & Guidelines
June 2011, Vol 2, No 3
A new analysis of the Humana database shows that the 21-gene recurrence score (RS) molecular assay (OncotypeDX; Genomic Health) leads to targeted management of early-stage breast cancer and reduces payer’s costs (Hornberger J, et al.
J Oncol Pract
. 2011;7[3s]:e38s-e45s).
Read Article
Significant Advances in Lung Cancer Highlighted at AACR
By
Caroline Helwick
AACR Annual Meeting
June 2011, Vol 2, No 3
Orlando, FL—Lung cancer studies made news at the 2011 American Association of Cancer Research annual meeting.
Read Article
Oral Oncolytics Abandoned by 1 of 10 Patients with Cancer
ASCO
,
ASCO Annual Meeting
June 2011, Vol 2, No 3
Chicago, IL—One of every 10 patients with cancer abandons new prescriptions for oral oncolytics, according to a study presented at the American Society of Clinical Oncology 2011 annual meeting and concurrently published in the
Journal of Oncology Practice
(Streeter SB, et al. 2011; 7:46-51).
Read Article
Exemestane Reduces First Invasive Breast Cancer by 65%
ASCO
,
ASCO Annual Meeting
June 2011, Vol 2, No 3
Chicago, IL—Exemestane (Aromasin) appears to be a good alternative to tamoxifen (Nolvadex) for prevention of breast cancer in postmenopausal women, according to results of the randomized, placebo-controlled MAP.3 trial reported at ASCO 2011.
Read Article
Oncologist Calls for Shorter Time to Approval of High-Value Targeted Cancer Drugs
Value Propositions
,
Value Peer-spectives
June 2011, Vol 2, No 3
New understanding of the mechanism of cancer as genetic and molecular cancer–causing lesions has enabled the development of targeted therapies that are producing excellent results in early clinical trials.
Read Article
Florida Cancer Network Adds Web-Based Treatment Tool to Address Quality, Cost Issues
Value Propositions
,
Value Peer-spectives
June 2011, Vol 2, No 3
The Florida Comprehensive Care Network (FCCN), a statewide network of medical and radiation oncologists providing comprehensive, evidence-based care to patients with cancer, has signed an agreement with ITA Partners that allows FCCN to use ITA’s oncology decision-support platform (called eviti) across its network of oncologists.
Read Article
Small but Positive Reductions in Some Cancer Death Rates
Value Propositions
,
Value Peer-spectives
June 2011, Vol 2, No 3
A new report published in March in the
Journal of the National Cancer
Institute
(2011;103:714-736) shows slow but consistent reductions in some cancer types in men and women between 2003 and 2007, the most recent years for which data are available.
Read Article
Researchers Discover 2 Molecules Involved in Cancer Metastasis
Value Propositions
,
Value Peer-spectives
June 2011, Vol 2, No 3
Researchers from Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, identified 2 regulatory molecules that enable a tumor, which originally is usually not deadly, to metastasize.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma